Regencell Bioscience Holdings Limited

NasdaqCM RGC

Regencell Bioscience Holdings Limited Shares (Diluted, Weighted) for the year ending June 30, 2024: 13,012,866

Regencell Bioscience Holdings Limited Shares (Diluted, Weighted) is 13,012,866 for the year ending June 30, 2024, a 0.00% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Regencell Bioscience Holdings Limited Shares (Diluted, Weighted) for the year ending June 30, 2023 was 13,012,866, a 0.00% change year over year.
Regencell Bioscience Holdings Limited Shares (Diluted, Weighted) for the year ending June 30, 2022 was 13,012,866, a 2.93% change year over year.
Regencell Bioscience Holdings Limited Shares (Diluted, Weighted) for the year ending June 30, 2021 was 12,642,105, a 0.00% change year over year.
Regencell Bioscience Holdings Limited Shares (Diluted, Weighted) for the year ending June 30, 2020 was 12,642,105, a 0.00% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqCM: RGC

Regencell Bioscience Holdings Limited

CEO	Mr. Yat-Gai Au
IPO Date	July 16, 2021
Location	Hong Kong
Headquarters	First Commercial Building
Employees	12
Sector	Health Care
Industries Biotechnology Pharmaceuticals Research & Consulting

Description

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Key trends

Past 5 years